The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Is experimental Alzheimer’s drug aducanumab being resurrected based on ‘bad’ data?

| | November 5, 2019

I worked on and around aducanumab, an experimental treatment for Alzheimer’s, for years during my time at Biogen. I thought it was going to work. I wanted it to work.

[I have seen] companies hem and haw at negative results and claim that if you squint and look sideways that the molecule really did work, hoping that investors would have mercy on the stock price — and in the process ignoring the responsibility to be honest and forthcoming to patients and their families.

When I learned last week that Biogen had completed a retrospective analysis of the aducanumab data — the same data that seven months earlier the company had said justified stopping work on the drug — I thought of my father, my friend, George Scangos, and people around the globe with Alzheimer’s, ALS, and other diseases for which there are no cures.

Related article:  Viewpoint: Targeting amyloid deposits isn’t working. It's time for a new approach for Alzheimer’s treatments

I hope that Biogen made a mistake in its futility analysis back in March. But if it didn’t, and this is another example of the American public watching big pharma trying to spin bad data, then I can’t help but wonder if Biogen, and perhaps the industry, has lost its way.

Read full, original post: I used to work on Biogen’s Alzheimer’s drug. Is the company spinning bad data?

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend